LP757
Advanced renal cell carcinoma and other solid tumors
NDA filingActive
Key Facts
Indication
Advanced renal cell carcinoma and other solid tumors
Phase
NDA filing
Status
Active
Company
About Lotus Pharmaceuticals
Taiwan‑based specialty pharma delivering oncology‑focused generics, biosimilars and NCEs across 90+ markets.
View full company profile